(News Bulletin 247) – AstraZeneca announces that a phase III trial showed that Tagrisso (osimertinib) produced a statistically and clinically significant improvement in overall survival (OS) compared to placebo in the adjuvant treatment of cancer patients early-stage (IB, II, and IIIA) non-small cell lung (NSCLC) with epidermal growth factor receptor (EGFRm) mutation after complete resection of the tumor with curative intent.
‘The results of this study provide strong evidence that osimertinib provides the best possible care for patients with early-stage EGFR-mutated non-small cell lung cancer who have historically faced high rates of recurrence and previously had no targeted options after surgery,” commented Roy S. Herbst, associate director and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut.
Furthermore, the safety and tolerability of Tagrisso in the trial were consistent with its established profile and no new safety issues were reported.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
